116 related articles for article (PubMed ID: 18637667)
1. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship.
Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Fedrizzi G; Ferrari P; Giacalone G; Giubileo M; Marazzi G; Micheletti R; Moro B; Pozzi M; Scotti PE; Torri M; Cerri A
J Med Chem; 2008 Aug; 51(15):4601-8. PubMed ID: 18637667
[TBL] [Abstract][Full Text] [Related]
2. Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Ferrari P; Giacalone G; Marazzi G; Moro B; Micheletti R; Sputore S; Torri M; Zappavigna MP; Cerri A
Bioorg Med Chem; 2010 Jun; 18(12):4275-99. PubMed ID: 20494582
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds.
De Munari S; Cerri A; Gobbini M; Almirante N; Banfi L; Carzana G; Ferrari P; Marazzi G; Micheletti R; Schiavone A; Sputore S; Torri M; Zappavigna MP; Melloni P
J Med Chem; 2003 Aug; 46(17):3644-54. PubMed ID: 12904068
[TBL] [Abstract][Full Text] [Related]
4. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).
Micheletti R; Mattera GG; Rocchetti M; Schiavone A; Loi MF; Zaza A; Gagnol RJ; De Munari S; Melloni P; Carminati P; Bianchi G; Ferrari P
J Pharmacol Exp Ther; 2002 Nov; 303(2):592-600. PubMed ID: 12388640
[TBL] [Abstract][Full Text] [Related]
6. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
7. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
8. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms.
Rocchetti M; Besana A; Mostacciuolo G; Ferrari P; Micheletti R; Zaza A
J Pharmacol Exp Ther; 2003 May; 305(2):765-71. PubMed ID: 12606646
[TBL] [Abstract][Full Text] [Related]
9. Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity.
Alemanni M; Rocchetti M; Re D; Zaza A
J Mol Cell Cardiol; 2011 May; 50(5):910-8. PubMed ID: 21354172
[TBL] [Abstract][Full Text] [Related]
10. A new approach to the design of novel inhibitors of Na+,K+-ATPase: 17alpha-substituted seco-D 5beta-androstane as cassaine analogues.
De Munari S; Barassi P; Cerri A; Fedrizzi G; Gobbini M; Mabilia M; Melloni P
J Med Chem; 1998 Jul; 41(16):3033-40. PubMed ID: 9685243
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.
Alevizopoulos K; Dimas K; Papadopoulou N; Schmidt EM; Tsapara A; Alkahtani S; Honisch S; Prousis KC; Alarifi S; Calogeropoulou T; Lang F; Stournaras C
Oncotarget; 2016 Apr; 7(17):24415-28. PubMed ID: 27027435
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, cardiotonic activity, and structure-activity relationships of 17 beta-guanylhydrazone derivatives of 5 beta-androstane-3 beta, 14 beta-diol acting on the Na+,K(+)-ATPase receptor.
Cerri A; Serra F; Ferrari P; Folpini E; Padoani G; Melloni P
J Med Chem; 1997 Oct; 40(21):3484-8. PubMed ID: 9341924
[TBL] [Abstract][Full Text] [Related]
13. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
14. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
[TBL] [Abstract][Full Text] [Related]
15. 17beta-O-Aminoalkyloximes of 5beta-androstane-3beta,14beta-diol with digitalis-like activity: synthesis, cardiotonic activity, structure-activity relationships, and molecular modeling of the Na(+),K(+)-ATPase receptor.
Cerri A; Almirante N; Barassi P; Benicchio A; Fedrizzi G; Ferrari P; Micheletti R; Quadri L; Ragg E; Rossi R; Santagostino M; Schiavone A; Serra F; Zappavigna MP; Melloni P
J Med Chem; 2000 Jun; 43(12):2332-49. PubMed ID: 10882359
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of novel sodium/potassium-ATPase inhibitors by virtual screening of a compound database.
Stanton DT; Ankenbauer J; Rothgeb D; Draper M; Paula S
Bioorg Med Chem; 2007 Sep; 15(18):6062-70. PubMed ID: 17618121
[TBL] [Abstract][Full Text] [Related]
17. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Na+,K(+)-ATPase by flavonoids and their inotropic effect. Investigation of the structure-activity relationship.
Umarova FT; Khushbactova ZA; Batirov EH; Mekler VM
Membr Cell Biol; 1998; 12(1):27-40. PubMed ID: 9829256
[TBL] [Abstract][Full Text] [Related]
19. Different Na+/K+-ATPase signal pathways was involved in the increase of [Ca2+]i induced by strophanthidin in normal and failing isolated guinea pig ventricular myocytes.
Qi YJ; Su SW; Li JX; Li JH; Guo F; Wang YL
Acta Pharmacol Sin; 2008 Nov; 29(11):1313-8. PubMed ID: 18954525
[TBL] [Abstract][Full Text] [Related]
20. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
